Teva Comments on Supreme Court Decision

JERUSALEM--(BUSINESS WIRE)-- Teva is pleased with the High Court’s decision today, which provides great clarity for both the drug industry as well as patients. This ruling reiterates that once the U.S. Food and Drug Administration approves a generic prescription drug as interchangeable to the brand, their labels must also be identical in all material respects. Accordingly, generic companies do not have the ability to influence labeling and related information and should not be held liable for failing to do so.

This is also a win for American consumers as they bear the ultimate burden of these lawsuits. The decision of the Supreme Court will help to alleviate unnecessary litigation.

Teva’s top priority is the quality of our products and the safety of our patients.



CONTACT:

Teva Pharmaceutical Industries Ltd.
Denise Bradley, 215-591-8974
[email protected]

KEYWORDS:   United States  North America  New York  Middle East  Israel

INDUSTRY KEYWORDS:   Health  Public Policy/Government  Courts  Pharmaceutical  FDA

MEDIA:

Suggested Articles

An oncologist leader RBC Capital Markets interviewed expressed comfort that Trodelvy will succeed in earlier-line TNBC and in HR-positive disease.

Gilead Sciences is the latest drugmaker to settle Justice Department claims that its charity contributions were actually kickbacks.

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.